ECSP045088A - Forma polimorfica de rimonabant, su procedimiento de preparacion y composiciones farmaceuticas que la contienen - Google Patents

Forma polimorfica de rimonabant, su procedimiento de preparacion y composiciones farmaceuticas que la contienen

Info

Publication number
ECSP045088A
ECSP045088A EC2004005088A ECSP045088A ECSP045088A EC SP045088 A ECSP045088 A EC SP045088A EC 2004005088 A EC2004005088 A EC 2004005088A EC SP045088 A ECSP045088 A EC SP045088A EC SP045088 A ECSP045088 A EC SP045088A
Authority
EC
Ecuador
Prior art keywords
rimonabant
pharmaceutical compositions
compositions containing
polymorphic form
preparation procedure
Prior art date
Application number
EC2004005088A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP045088A publication Critical patent/ECSP045088A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un nuevo polimorfo cristalino de rimonabant, a su modo de preparación y a las composiciones farmacéuticas que contienen ese nuevo polimorfo.
EC2004005088A 2001-11-08 2004-04-27 Forma polimorfica de rimonabant, su procedimiento de preparacion y composiciones farmaceuticas que la contienen ECSP045088A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0114579A FR2831883B1 (fr) 2001-11-08 2001-11-08 Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant

Publications (1)

Publication Number Publication Date
ECSP045088A true ECSP045088A (es) 2004-06-28

Family

ID=8869285

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005088A ECSP045088A (es) 2001-11-08 2004-04-27 Forma polimorfica de rimonabant, su procedimiento de preparacion y composiciones farmaceuticas que la contienen

Country Status (33)

Country Link
US (2) US20050043356A1 (es)
EP (1) EP1446384A1 (es)
JP (2) JP4181994B2 (es)
KR (2) KR20090089485A (es)
CN (1) CN100412063C (es)
AP (1) AP1830A (es)
AR (1) AR037253A1 (es)
AU (1) AU2002350869B2 (es)
BR (1) BR0213931A (es)
CA (1) CA2464145A1 (es)
CO (1) CO5580827A2 (es)
CR (1) CR7333A (es)
EA (1) EA006771B1 (es)
EC (1) ECSP045088A (es)
FR (1) FR2831883B1 (es)
GE (1) GEP20063894B (es)
HR (1) HRP20040403A2 (es)
HU (1) HUP0402043A3 (es)
IL (2) IL161533A0 (es)
IS (1) IS7226A (es)
MA (1) MA27080A1 (es)
ME (1) MEP21908A (es)
MX (1) MXPA04004394A (es)
NO (1) NO326648B1 (es)
NZ (1) NZ532369A (es)
OA (1) OA12721A (es)
PL (1) PL369372A1 (es)
RS (1) RS36904A (es)
TN (1) TNSN04079A1 (es)
TW (1) TW200302824A (es)
UA (1) UA76776C2 (es)
WO (1) WO2003040105A1 (es)
ZA (1) ZA200402999B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2831883B1 (fr) * 2001-11-08 2004-07-23 Sanofi Synthelabo Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
US6932971B2 (en) 2002-07-18 2005-08-23 Cytos Biotechnology Ag Hapten-carrier conjugates and uses thereof
FR2861992B1 (fr) * 2003-11-10 2007-07-20 Sanofi Synthelabo Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide.
NZ564759A (en) 2005-06-30 2011-08-26 Prosidion Ltd GPCR agonists
EP1816125A1 (en) * 2006-02-02 2007-08-08 Ranbaxy Laboratories, Ltd. Novel crystalline forms of an antagonist of CB1 cannabinoid receptor and preparation method thereof
FR2897060B1 (fr) * 2006-02-08 2008-07-25 Sanofi Aventis Sa Le monohydrate de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
AR061606A1 (es) * 2006-06-22 2008-09-10 Medichem Sa Formas solidas de rimonabant y procesos para su preparacion
WO2008044153A2 (en) * 2006-08-29 2008-04-17 Medichem, S.A. Improved method for synthesizing rimonabant
WO2008026219A2 (en) * 2006-09-01 2008-03-06 Hetero Drugs Limited Novel polymorphs of rimonabant
EP2061783A2 (en) * 2006-09-11 2009-05-27 Hetero Drugs Limited Improved process for rimonabant
WO2008035023A1 (en) * 2006-09-19 2008-03-27 Cipla Limited Polymorphs of rimonabant
WO2008056377A2 (en) * 2006-11-06 2008-05-15 Cadila Healthcare Limited Polymorphic forms of rimonabant
WO2008064615A2 (en) * 2006-12-01 2008-06-05 Zentiva, A.S. Crystalline and amorphous forms of rimonabant and processes for obtaining them
MX2009006214A (es) * 2006-12-18 2009-06-22 7Tm Pharma As Moduladores del receptor cb1.
CL2008000018A1 (es) 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
BRPI0806312A2 (pt) 2007-01-04 2011-09-06 Prosidion Ltd agonistas cgpr piperidina
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
AR064736A1 (es) 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr
ES2373181T3 (es) 2007-01-04 2012-02-01 Prosidion Ltd Agonistas de gpcr de piperidina.
EP1944297A1 (en) * 2007-01-09 2008-07-16 Miklós Vértessy Solid and crystalline rimonabant and processes for preparation, and pharmaceutical composition thereof
WO2008088900A2 (en) * 2007-01-18 2008-07-24 Teva Pharmaceutical Industries Ltd. Polymorphic forms of rimonabant base and processes for preparation thereof
EP1953144A1 (en) 2007-01-30 2008-08-06 Sandoz AG Novel polymorphic forms of N-piperidino-5-(4-chlorophenyl)-1-(2, 4-dichlorphenyl)-4-methyl-3-pyrazolecarboxamide
FR2919862A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de 3-methylbutan-1-ol de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
FR2919863A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de n-methylpyrrolidone de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
FR2919865A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de dmso de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
FR2919867A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de 2-methoxyethanol de rimonabant et son procede de preparation
FR2919864A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de 1,4-dioxane de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
WO2009153804A1 (en) * 2008-06-16 2009-12-23 Cadila Healthcare Limited Process for preparing form i of rimonabant
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
FR3008620A1 (fr) * 2013-07-22 2015-01-23 Sanofi Sa Formulation de comprime d'un inhibiteur de phosphatidylinositol 3-kinase
US20240140910A1 (en) * 2019-10-16 2024-05-02 Otsuka Pharmaceutical Co., Ltd. Method for producing centanafadine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
AU2002331595A1 (en) * 2001-08-15 2003-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Novel vasoconstrictor cannabinoid analogs
FR2831883B1 (fr) * 2001-11-08 2004-07-23 Sanofi Synthelabo Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant

Also Published As

Publication number Publication date
IL161533A0 (en) 2004-09-27
IS7226A (is) 2004-04-19
WO2003040105A1 (fr) 2003-05-15
AP1830A (en) 2008-02-22
GEP20063894B (en) 2006-08-10
KR20050043774A (ko) 2005-05-11
NZ532369A (en) 2005-10-28
AR037253A1 (es) 2004-11-03
ZA200402999B (en) 2005-04-20
AU2002350869B2 (en) 2007-07-26
UA76776C2 (uk) 2006-09-15
HUP0402043A3 (en) 2009-07-28
CN100412063C (zh) 2008-08-20
EA200400491A1 (ru) 2004-12-30
NO326648B1 (no) 2009-01-26
FR2831883A1 (fr) 2003-05-09
AP2004003024A0 (en) 2004-06-30
RS36904A (en) 2006-10-27
MXPA04004394A (es) 2004-08-11
EP1446384A1 (fr) 2004-08-18
JP2009035547A (ja) 2009-02-19
TW200302824A (en) 2003-08-16
OA12721A (fr) 2006-06-27
NO20041879D0 (no) 2004-05-07
MEP21908A (en) 2010-06-10
HUP0402043A2 (hu) 2005-01-28
CA2464145A1 (en) 2003-05-15
US20050043356A1 (en) 2005-02-24
CN1582278A (zh) 2005-02-16
CR7333A (es) 2008-09-23
JP2005508383A (ja) 2005-03-31
JP4181994B2 (ja) 2008-11-19
IL161533A (en) 2010-05-31
PL369372A1 (en) 2005-04-18
FR2831883B1 (fr) 2004-07-23
HRP20040403A2 (en) 2004-08-31
KR20090089485A (ko) 2009-08-21
CO5580827A2 (es) 2005-11-30
NO20041879L (no) 2004-06-08
BR0213931A (pt) 2004-09-08
MA27080A1 (fr) 2004-12-20
EA006771B1 (ru) 2006-04-28
JP4931874B2 (ja) 2012-05-16
TNSN04079A1 (fr) 2006-06-01
US20100190827A1 (en) 2010-07-29

Similar Documents

Publication Publication Date Title
ECSP045088A (es) Forma polimorfica de rimonabant, su procedimiento de preparacion y composiciones farmaceuticas que la contienen
MXPA05009969A (es) Metodo para aislar la forma cristalina i de la 5-azacitidina.
NO20071050L (no) Rapamycin-polymorf II og anvendelser derav
MX2007005221A (es) Formas cristalinas de ascomicina y preparacion de ellas.
WO2004082619A3 (en) Forms of 5-azacytidine
SE0101675D0 (sv) Novel composition
IS7261A (is) N-adamantýlmetýlafleiður og milliefni sem lyfjablöndur og aðferðir til að framleiða þær
DK1756049T3 (da) Fremgangsmåde til fremstilling af 1,4-diphenylazetidinon-derivater
DK1546122T3 (da) Fremgangsmåde til fremstilling af valsartan
ZA200404752B (en) 6-aminomorphinane derivatives method for the production and use thereof
TW200420541A (en) Crystalline forms
DK1667967T3 (da) Fremgangsmåde til fremstilling af 2-oxo-1-pyrrolidin-derivater
TNSN04024A1 (en) Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation
NO20073725L (no) CCI-779-polymorf og dens anvendelse
NO20044814L (no) Fremgangsmate for fremstilling av combretastaniner
WO2004074350A3 (en) Bicalutamide polymorphs
DK1456229T3 (da) Fremgangsmåe til fremstilling af echinocandin-derivater
PL1507531T3 (pl) Trwałe kompozycje farmaceutyczne desloratadyny
DK1678135T3 (da) Fremgangsm de til fremstilling af n-amino-substituerede hetorocykliske forbindelser
EP1646640A4 (en) PROCESS FOR PREPARING HIGH-PURITY 1-ANDROSTEN DERIVATIVES
DK1692137T3 (da) Fremgangsmåde til fremstilling af tubulinininhibitorer
NO20052396D0 (no) Fremgangsmate for fremstilling av spirolactonforbindelser
UY27743A1 (es) Forma poliforma de rimonabant su procedimiento de preparación y composición farmacéuticas que la contienen.
DK1685104T3 (da) Fremgangsmåde til fremstilling af N-substituerede phthalomider
DK1692105T3 (da) Fremgangsmåde til fremstilling af (3-oxo-2,3-dihydro-1H-isoindol-1-yl)-acetylguanidin-derivater